61098-38-2

Usage

Uses

Used in Pharmaceutical Development:
5,7-dichloro-6-methylpyrazolo[1,5-a]pyrimidine is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Research:
5,7-dichloro-6-methylpyrazolo[1,5-a]pyrimidine is used as a starting material in the development of agrochemicals. Its potential biological activities make it a promising candidate for the creation of new pesticides or herbicides.
Used in Medicinal Chemistry Research:
5,7-dichloro-6-methylpyrazolo[1,5-a]pyrimidine is used as a research tool in medicinal chemistry. Its unique structure and potential biological activities make it a valuable molecule for studying the mechanisms of action and developing new therapeutic agents.
Used in Drug Discovery:
5,7-dichloro-6-methylpyrazolo[1,5-a]pyrimidine is used in drug discovery efforts to identify new lead compounds with potential therapeutic applications. Its unique structure and potential biological activities make it a promising candidate for the development of novel drugs.

Upstream product

• 1820-80-0 3-aminopyrazole 
• 609-08-5 Diethyl methylmalonate 
• 57489-71-1 6-methylpyrazolo[1,5-a]pyrimidine-5,7-diol 
• 10025-87-3 trichlorophosphate 

Downstream Products

• 754211-10-4 5-chloro-N-(2-chlorophenyl)-6-methylpyrazolo[1,5-a]pyrimidin-7-amine 
• 1273190-06-9 3-chloro-4-(7-(cyclopropylamino)-3-formyl-6-methylpyrazolo[1,5-a]pyrimidin-5-ylamino)benzonitrile 
• 1273190-08-1 5-(4-(1H-pyrazol-1-yl)phenylamino)-7-(cyclopropylamino)-6-methylpyrazolo[1,5-a]pyrimidine-3-carbaldehyde 
• 1393882-51-3 tert-butyl N-(4-bromophenyl)-N-{5-chloro-6-methylpyrazolo[1,5-a]pyrimidin-7-yl}carbamate 
• 754204-64-3 5-N-(trans-4-aminocyclohexyl)-7-N-(3-chloro-4-fluorophenyl)-6-methylpyrazolo[1,5-a]pyrimidine-5,7-diamine 
• 754204-96-1 5-N-(trans-4-aminocyclohexyl)-7-N-(4-ethoxyphenyl)-6-methylpyrazolo[1,5-a]pyrimidine-5,7-diamine 
• 1393882-27-3 5-chloro-N-(cyclohexylmethyl)-6-methylpyrazolo[1,5-a]pyrimidin-7-amine 
• 1393882-29-5 ethyl 4-({5-chloro-6-methylpyrazolo[1,5-a]pyrimidin-7-yl}amino)benzoate 
• 1393882-28-4 5-chloro-N-(3-chloro-4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-amine 
• 1393882-33-1 N-(4-bromophenyl)-5-chloro-6-methylpyrazolo[1,5-a]pyrimidin-7-amine 
• 1393882-30-8 5-chloro-N-(3-ethoxyphenyl)-6-methylpyrazolo[1,5-a]pyrimidin-7-amine 
• 1393882-50-2 tert-butyl N-[3-(benzyloxy)phenyl]-N-{5-chloro-6-methylpyrazolo[1,5-a]pyrimidin-7-yl}carbamate 
• 1393882-49-9 ethyl 3-{[(tert-butoxy)carbonyl]({5-chloro-6-methylpyrazolo[1,5-a]pyrimidin-7-yl})amino}benzoate 
• 1393882-48-8 tert-butyl N-{5-chloro-6-methylpyrazolo[1,5-a]pyrimidin-7-yl}-N-(3-ethoxyphenyl)carbamate 

Relevant academic research and scientific papers

MACROCYCLIC RIP2-KINASE INHIBITORS

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2-kinase, and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.

Pyrazolopyrimidines and related heterocycles as CK2 inhibitors

The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:

Pyrazolopyrimidin CK2 and related heterocyclic compound as an inhibitor

The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:

MK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: Discovery and in vivo activity of selective pyrazolo[1,5- a ]pyrimidine inhibitors using a focused library and structure-based optimization approach

A novel class of mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) inhibitors was discovered through screening a kinase-focused library. A homology model of MAPKAP-K2 was generated and used to guide the initial SAR studies and to rationalize the observed selectivity over CDK2. An X-ray crystal structure of a compound from the active series bound to crystalline MAPKAP-K2 confirmed the predicted binding mode. This has enabled the discovery of a series of pyrazolo[1,5-a]pyrimidine derivatives showing good in vitro cellular potency as anti-TNF-α agents and in vivo efficacy in a mouse model of endotoxin shock.

Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF1) receptor antagonists

To identify structurally novel CRF1 receptor antagonists, a series of bicyclic core antagonists, pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a] pyrimidines, imidazo[1,2-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines were designed, synthesized and evaluated as CRF1 receptor antagonists. Compounds 2-27 showed binding affinity (IC50 = 4.2-418 nM) and antagonist activity (EC50 = 4.0-889 nM). Compound 5 was found to show oral efficacy in an Elevated Plus Maze test in rats. Further chemical modification of them led us to discovery of the tricyclic core antagonists pyrazolo[1,5-a]pyrrolo[3,2-e] pyrimidines. The discovery process of these compounds is presented, as is the study of the structure-activity relationship.

PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS

The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, infections, and certain immunological disorders.

Methods for inhibiting protein kinases

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevent

Pyrazolopyrimidines as protein kinase inhibitors

In its many embodiments, the present invention provides a novel class of amino-substituted pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including o